Back to results
US 2026/0308185 A1Published application
Stat degraders and uses thereof
AssigneeRecludix Pharma, Inc.
InventorsNeil Bifulco, Howard Bregman, Giovanni Cianchetta, Brian Hodous, Samuel K. Reznik, Yong Tang, Andrew Tasker, Rishi G. Vaswani, Ernest Allen Sickmier, Xia Tian, John Yeoman
Life of this patent
Estimating the term…
Abstract
Provided are compounds of Formula (I): (I) and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with STAT3 and/or STAT6.
Claims39
A compound having the structural formula I:
- or a pharmaceutically acceptable salt thereof, wherein:
- q is 0 or 1 and t is 0, 1, or 2, provided that at least one of q or t is 1;
- p is 1 or 2;
- R1 is selected from an 8- to 10-membered fused bicyclic heteroaryl substituted with —CR1aR2aP(O)OR1bOR2b, —CR1aR2aP(O)[OR1b][NH(AA)C(O)ORT], —CR1aR2aP(O)[NHRTy][NH(AA)C(O)ORT], —P(O)OR1bOR2b, —[P(O)[NHRTy][NH(AA)C(O)ORT], —CR1aR2aP(O)[NH(AA)C(O)ORT]][NH(AA)C(O)ORT], or —P(O)[OR1b][NH(AA)C(O)ORT];
- an 8- to 10-membered fused bicyclic heterocyclyl substituted with —CR1aR2aP(O)OR1bOR2b, —CR1aR2aP(O)[OR1b][NH(AA)C(O)ORT], —CR1aR2aP(O)[NHRTy][NH(AA)C(O)ORT], —P(O)OR1bOR2b, —[P(O)[NHRTy][NH(AA)C(O)ORT], —CR1aR2aP(O)[NH(AA)C(O)ORT]][NH(AA)C(O)ORT], or —P(O)[OR1b][NH(AA)C(O)ORT];
- an aryl substituted with —CR1aR2aP(O)OR1bOR2b, CR1aR2aP(O)[OR1b][NH(AA)C(O)ORT], —CR1aR2aP(O)[NHRTy][NH(AA)C(O)ORT], —P(O)OR1bOR2b, —[P(O)[NHRTy][NH(AA)C(O)ORT], —CR1aR2aP(O)[NH(AA)C(O)ORT]][NH(AA)C(O)ORT], or —P(O)[OR1b][NH(AA)C(O)ORT], a —(C1-C4)alkyl(aryl) wherein said aryl portion of —(C1-C4)alkyl(aryl) is substituted with —CR1aR2aP(O)OR1bOR2b, —CR1aR2aP(O)[OR1b][NH(AA)C(O)ORT], —CR1aR2aP(O)[NHRTy][NH(AA)C(O)ORT], —P(O)OR1bOR2b, —[P(O)[NHRTy][NH(AA)C(O)ORT], or —CR1aR2aP(O)[NH(AA)C(O)ORT]][NH(AA)C(O)ORT], —P(O)[OR1b][NH(AA)C(O)ORT];
- and a —(C2-C4)alkenyl(aryl) wherein said aryl portion of —(C2-C4)alkenyl(aryl) is substituted with —CR1aR2aP(O)OR1bOR2b, —CR1aR2aP(O)[OR1b][NH(AA)C(O)ORT], —CR1aR2aP(O)[NHRTy][NH(AA)C(O)ORT], —P(O)OR1bOR2b, —[P(O)[NHRTy][NH(AA)C(O)ORT], —CR1aR2aP(O)[NH(AA)C(O)ORT]][NH(AA)C(O)ORT], or —P(O)[OR1b][NH(AA)C(O)ORT];
- R1a and R2a are each independently selected from hydrogen, cyano, (C1-C4)alkyl, hydroxy(C1-C4)alkyl and fluoro;
- or R1a and R2a taken together with the carbon they are attached form oxo;
- R1b and R2b are each independently selected from hydrogen, (C1-C4)alkyl, halo(C1-C4)alkyl, —[(C1-C4)alkyl]-OC(O)—[(C1-C4)alkyl], —[(C1-C4)alkyl]-C(O)O—[(C1-C4)alkyl], —[(C1-C4)alkyl]-O—[(C1-C20)alkyl], —[(C1-C4)alkyl]-OC(O)-[halo(C1-C4)alkyl], [(C1-C4)alkyl]-OC(O)O-[5- to 7-membered heterocyclyl], [(C1-C4)alkyl]-OC(O)-[5- to 7-membered heterocyclyl], —[(C1-C4)alkyl]-OC(O)—[(C1-C4)alkyl]-OH, —[(C1-C4)alkyl]-OC(O)—[(C1-C4)alkyl]-O—[(C1-C4)alkyl], —[(C1-C4)alkyl]-OC(O)O)—[(C1-C4)alkyl], —[(C1-C4)alkyl]-OC(O)O-[halo(C1-C4)alkyl], —[(C1-C4)alkyl]-OC(O)O—[(C1-C4)alkyl]-OH, —[(C1-C4)alkyl]-OC(O)O—[(C1-C4)alkyl]-O—[(C1-C4)alkyl], —[(C1-C4)alkylphenyl]-C(O)O—[(C1-C4)alkyl], —[(C1-C4)alkyl]-OC(O)—[NH(AA)C(O)ORT], —[(C1-C4)alkyl]-SC(O)—[(C1-C4)alkyl], —[(C1-C4)alkyl]-SC(O)-[halo(C1-C4)alkyl], —[(C1-C4)alkyl]-SC(O)—[(C1-C4)alkyl]-OH, —[(C1-C4)alkyl]-SC(O)—[(C1-C4)alkyl]-O—[(C1-C4)alkyl], —[(C1-C4)alkyl]-OC(O)NH(C1-C4)alkyl], —[(C1-C4)alkyl]-OC(O)N[(C1-C4)alkyl]2, and aryl, wherein said 5- to 6-membered heteroaryl and aryl are each optionally and independently substituted with, as valency permits, 1 to 2 groups selected from halo, cyano, and (C1-C4)alkyl and wherein said 5- to 7-membered heterocyclyl of [(C1-C4)alkyl]-OC(O)O-[5- to 7-membered heterocyclyl] and [(C1-C4)alkyl]-OC(O)-[5- to 7-membered heterocyclyl] are each optionally and independently substituted with, as valency permits 1 to 2 groups selected from C(O)ORh;
- R2 is selected from hydrogen, halo, (C1-C4)alkyl, halo(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, hydroxy(C1-C4)alkyl, cyano, and hydroxyl;
- R3 and R4 are each independently selected from hydrogen, halo, and (C1-C4)alkyl;
- R5 and R6 are each independently selected from hydrogen, phenyl, and (C1-C4)alkyl;
- R7 is selected from E, —R10AE, (C1-C4)alkyl, phenyl, 4- to 9-membered monocyclic or bicyclic heterocyclyl, and 5- to 10-membered monocyclic or bicyclic heteroaryl, wherein said (C1-C4)alkyl is optionally substituted with, as valency permits, 1 to 3 groups selected from RY and said phenyl, 4- to 9-membered monocyclic or bicyclic heterocyclyl, and 5- to 10-membered monocyclic or bicyclic heteroaryl are each optionally substituted with, as valency permits, R11 and/or 1 to 3 groups selected from RZ;
- or
- R6 and R7 together with the nitrogen atom to which they are attached form a 4- to 14-membered monocyclic or bicyclic heterocyclyl or a 5- to 12-membered monocyclic or bicyclic heteroaryl, each of which being optionally substituted with, as valency permits, R12 and/or 1 to 3 groups selected from RQ;
- R8 is hydrogen or (C1-C4)alkyl;
- R10A, R10D, R10C, and R10D are each independently a chemical spacer unit;
- R11 is selected from —NHC(O)R10BE, —OR10BE, phenyl, (C3-C6)cycloalkyl, 5- to 6-membered heteroaryl, and 4- to 6-membered heterocyclyl each of said phenyl, (C3-C6)cycloalkyl, 5- to 6-membered heteroaryl, and 4- to 6-membered heterocyclyl being substituted with —OR10BE, —NHR10BE, —[N(C1-C4)alkyl]R10BE, or R10BE, and wherein said 4- to 6-membered heterocyclyl is optionally substituted further with oxo;
- R12 is selected from —NHC(O)R10CE, —OR10CE, phenyl, (C3-C6)cycloalkyl, 5- to 6-membered heteroaryl, and 4- to 6-membered heterocyclyl each of said phenyl, (C3-C6)cycloalkyl, 5- to 6-membered heteroaryl, and 4- to 6-membered heterocyclyl being substituted with —OR10CE, —NHR10CE, —[N(C1-C4)alkyl]R10CE, or R10CE, and wherein said 4- to 6-membered heterocyclyl is optionally substituted further with oxo;
- R13 is selected from —NHC(O)R10DE, —OR10DE, phenyl, (C3-C6)cycloalkyl, 5- to 6-membered heteroaryl, and 4- to 6-membered heterocyclyl each of said phenyl, (C3-C6)cycloalkyl, 5- to 6-membered heteroaryl, and 4- to 6-membered heterocyclyl being substituted with —OR10DE, —NHR10DE, —[N(C1-C4)alkyl]R10DE, or R10DE, and wherein said 4- to 6-membered heterocyclyl is optionally substituted further with oxo;
- E is a chemical moiety that binds to E3 ligase;
- AA is the residue of an alpha or beta natural or non-natural amino acid;
- RT and RTy are each independently selected from (C1-C4)alkyl, (C1-C4)alkyl-C(O)O(C1-C4)alkyl, benzyl, and phenyl, wherein said phenyl is optionally substituted with 1 or 2 groups selected from halo, (C1-C4)alkyl, and halo(C1-C4)alkyl;
- RQ is selected from halo, (C2-C4)alkenyl, (C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, cyano, phenyl, hydroxyl, 4- to 9-membered monocyclic or bicyclic heterocyclyl, 5- to 10-membered monocyclic or bicyclic heteroaryl, (C3-C6)cycloalkyl, oxo, imino, —ORe, —C(O)Rg, —C(O)ORe, —NRcC(O)Re, —C(O)NRcRd, —NRaRb, —S(O)ReRf, —S(O)2Rf, —S(O)═NH(C1-C4)alkyl, —S(O)NReRf, and —S(O)2NReRf, wherein said (C3-C4)alkenyl and (C1-C4)alkyl are each optionally and independently substituted with, as valency permits, 1 to 3 groups selected from RM, and wherein said phenyl, 5- to 10-membered monocyclic or bicyclic heteroaryl, (C3-C6)cycloalkyl, and 4- to 9-membered monocyclic or bicyclic heterocyclyl are each optionally and independently substituted with, as valency permits, 1 to 3 groups selected from RF;
- RY is selected from halo, (C1-C4)alkoxy, halo(C1-C4)alkoxy, cyano, —C(O)Rg, —C(O)ORe, —NHC(O)Re, —NRaRb, —S(O)ReRf, —S(O)2Rf, —S(O)NReRf, —S(O)═NH(C1-C4)alkyl, —S(O)2NReRf, hydroxyl, phenyl, 4- to 6-membered heterocyclyl, and 5- to 10-membered monocyclic or bicyclic heteroaryl, wherein said phenyl, 4- to 6-membered heterocyclyl, and 5- to 10-membered monocyclic or bicyclic heteroaryl are each optionally substituted with, as valency permits, 1 to 3 groups selected from RX;
- RM and RJ are each independently selected from halo, (C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, cyano, —C(O)Rg, —C(O)ORe, —NHC(O)Re, —C(O)NRcRd, —NRaRb, —S(O)ReRf, —S(O)2Rf, —S(O)NReRf, —S(O)═NR(C1-C4)alkyl, —S(O)2NReRf, hydroxyl, phenyl, 4- to 6-membered heterocyclyl, and 5- to 10-membered monocyclic or bicyclic heteroaryl, wherein said phenyl, 4- to 6-membered heterocyclyl, and 5- to 10-membered monocyclic or bicyclic heteroaryl are each optionally substituted with, as valency permits, 1 to 3 groups selected from RX;
- RF and RX are each independently selected from halo, cyano, (C1-C4)alkyl, cyano(C1-C4)alkyl, (C3-C6)cycloalkyl, halo(C1-C4)alkyl, —(C1-C4)alkylC(O)NRcRd, —(C1-C4)alkyl(C1-C4)alkoxy, hydroxy(C1-C4)alkyl, —(C1-C4)alkylphenyl, —(C1-C4)alkylheteroaryl, (C2-C4)alkenyl, halo(C2-C4)alkenyl, (C2-C4)alkynyl, halo(C2-C4)alkynyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, —ORe, oxo, imino, phenyl, 4- to 6-membered heterocyclyl, 5- to 6-membered monocyclic heteroaryl —S(O)ReRf, —S(O)2Rf, —S(O)═NH(C1-C4)alkyl, —S(O)NReRf, —S(O)2NReRf, —C(O)ORc, —NRcC(O)Re, —(C1-C4alkyl)C(O)Rg, —C(O)Rg, —C(O)NRcRd, NO2, and —NRaRb, wherein said phenyl, said 4- to 6-membered heterocyclyl, and said phenyl for —(C1-C4)alkylphenyl are each optionally and independently substituted with, as valency permits 1 to 3 groups selected from halo, cyano, oxo, (C1-C10)alkyl, (C2-C10)alkenyl, (C2-C10)alkynyl, halo(C1-C10)alkyl, (C1-C10)alkoxy, —(C1-C4)alkyl(C1-C4)alkoxy, and halo(C1-C10)alkoxy, wherein said (C1-C10)alkyl, (C2-C10)alkenyl and (C2-C10)alkynyl are each optionally substituted with, as valency permits a 5- to 10-membered monocyclic or bicyclic heteroaryl or a 4- to 10-membered monocyclic or bicyclic heterocyclyl each of said 5- to 10-membered monocyclic and bicyclic heteroaryl or a 4- to 10-membered monocyclic or bicyclic heterocyclyl being optionally substituted with oxo or a 5- to 7-membered heterocyclyl that is optionally substituted with 1 to 2 oxo;
- RZ is selected from halo, cyano, (C1-C4)alkyl, (C3-C6cycloalkyl), halo(C1-C4)alkyl, —(C1-C4)alkyl(C1-C4)alkoxy, hydroxy(C1-C4)alkyl, —(C1-C4)alkylphenyl, —(C1-C4)alkylheteroaryl, (C2-C4)alkenyl, halo(C2-C4)alkenyl, (C2-C4)alkynyl, halo(C2-C4)alkynyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, —ORe, oxo, imino, phenyl, 4- to 6-membered heterocyclyl, —S(O)ReRf, —S(O)2Rf, —S(O)═NH(C1-C4)alkyl, —S(O)NReRf, and —S(O)2NReRf, —C(O)ORe, —NRcC(O)Rc, —(C1-C4alkyl)C(O)Rg, —C(O)Rg, —(C1-C4alkyl)C(O)NRcRd, —C(O)NRcRd, —NO2, and —NRaRb, wherein the (C1-C4)alkyl is optionally substituted with cyano, wherein said phenyl, said 4- to 6-membered heterocyclyl, and said phenyl for —(C1-C4)alkylphenyl are each optionally and independently substituted with, as valency permits R13 and/or 1 to 3 groups selected from halo, cyano, oxo, (C1-C10)alkyl, (C2-C10)alkenyl, (C2-C10)alkynyl, halo(C1-C10)alkyl, (C1-C10)alkoxy, and halo(C1-C10)alkoxy, wherein said (C1-C10)alkyl, (C2-C10)alkenyl and (C2-C10)alkynyl are each optionally substituted with, as valency permits a 5- to 10-membered monocyclic or bicyclic heteroaryl or a 4- to 10-membered monocyclic or bicyclic heterocyclyl each of said 5- to 10-membered monocyclic and bicyclic heteroaryl or a 4- to 10-membered monocyclic or bicyclic heterocyclyl being optionally substituted with oxo or a 5- to 7-membered heterocyclyl that is optionally substituted with 1 to 2 oxo;
- and
- Ra, Rh, Rc, Rd, Re, Rf, Rg, and Rh are each independently selected from, as valency permits, hydrogen, (C1-C4)alkyl, (C2-C4)alkynyl, —(C1-C4)alkylphenyl, phenyl, (C1-C6)cycloalkyl, 4- to 6-membered heterocyclyl and 5- to 6-membered heteroaryl, wherein said (C1-C4)alkyl is optionally substituted with, as valency permits, 1 to 3 groups selected from RJ, and said phenyl, (C3-C6)cycloalkyl, 4- to 6-membered heterocyclyl, and 5- to 6-membered heteroaryl are each independently optionally substituted with, as valency permits, 1 to 3 groups selected from halo, cyano, (C1-C4)alkyl, halo(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, hydroxyl, phenyl, and benzyl.
28 more elements
Dependencies are inferred from the claim text.